AlzChem Group AG
AlzChem Group AG Fundamental Analysis
AlzChem Group AG (ACT.DE) shows moderate financial fundamentals with a PE ratio of 29.18, profit margin of 11.29%, and ROE of 27.29%. The company generates $0.6B in annual revenue with weak year-over-year growth of 2.51%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 63.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze ACT.DE's fundamental strength across five key dimensions:
Efficiency Score
ExcellentACT.DE demonstrates superior asset utilization.
Valuation Score
WeakACT.DE trades at a premium to fair value.
Growth Score
ModerateACT.DE shows steady but slowing expansion.
Financial Health Score
ExcellentACT.DE maintains a strong and stable balance sheet.
Profitability Score
ModerateACT.DE maintains healthy but balanced margins.
Key Financial Metrics
Is ACT.DE Expensive or Cheap?
P/E Ratio
ACT.DE trades at 29.18 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, ACT.DE's PEG of 10.49 indicates potential overvaluation.
Price to Book
The market values AlzChem Group AG at 7.22 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 17.19 times EBITDA. This signals the market has high growth expectations.
How Well Does ACT.DE Make Money?
Net Profit Margin
For every $100 in sales, AlzChem Group AG keeps $11.29 as profit after all expenses.
Operating Margin
Core operations generate 14.73 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $27.29 in profit for every $100 of shareholder equity.
ROA
AlzChem Group AG generates $10.27 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
AlzChem Group AG produces operating cash flow of $101.47M, showing steady but balanced cash generation.
Free Cash Flow
AlzChem Group AG produces free cash flow of $30.86M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $3.05 in free cash annually.
FCF Yield
ACT.DE converts 1.66% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
29.18
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
10.49
vs 25 benchmark
P/B Ratio
Price to book value ratio
7.22
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.30
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.18
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.49
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.27
vs 25 benchmark
ROA
Return on assets percentage
0.10
vs 25 benchmark
ROCE
Return on capital employed
0.17
vs 25 benchmark
How ACT.DE Stacks Against Its Sector Peers
| Metric | ACT.DE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 29.18 | 24.08 | Worse (Expensive) |
| ROE | 27.29% | 921.00% | Weak |
| Net Margin | 11.29% | -113338.00% (disorted) | Strong |
| Debt/Equity | 0.18 | 0.53 | Strong (Low Leverage) |
| Current Ratio | 2.49 | 5.09 | Strong Liquidity |
| ROA | 10.27% | -9816.00% (disorted) | Strong |
ACT.DE outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews AlzChem Group AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
47.40%
Industry Style: Cyclical, Commodity, Value
High GrowthEPS CAGR
200.88%
Industry Style: Cyclical, Commodity, Value
High GrowthFCF CAGR
141.04%
Industry Style: Cyclical, Commodity, Value
High Growth